Tagged with LMI

Norway Karita Bekkemellem of Norwegian pharma association LMI highlights her work building up the profile of the industry in Norway, the market access and pricing challenges facing her member companies, and the country’s enduring potential as a leading clinical trial destination.   Through diligent and long-term thinking, and building bridges and…

Portugal Rui Ferreira Dos Santos, country manager for Spanish pharmaceutical company, Almirall provides readers with an update on the company’s new medicines and how their global strategy to become dermatology specialists manifests itself in Portugal. Rui also sheds light on the challenging yet rewarding pharmaceutical landscape, where new managers can learn,…

Canada Dwight Gorham, president and CEO of Pillar5 Pharma, discusses the unique positioning of the CDMO in the multi-dose preservative free sterile ophthalmics space and stresses the importance of anticipating market trends in order to fuel expansion. Finally, he gives an insight into the importance of honing new skills and how…

Pharma Riccardo Palmisano, CEO of MolMed, discusses the latest developments for their late-stage clinical development products, and comments on the recent approval of Strimvelis, a gene therapy developed by GSK and MolMed. Can you please give our readers a brief rundown of the history of MolMed since its foundation in 1996?…

Pharma Having successfully accomplished a four-year turnaround exercise and with a fresh capital injection from a leading Italian PE firm, SIFI executive chairman Fabrizio Chines has ambitious growth objectives for the coming years, and is investing in R&D projects including the development of an ophthalmic orphan drug. The Italian pharmaceutical industry…

Pharma The pharmaceutical industry needs to work harder to demonstrate the value that it delivers to society and to the greater economy by advancing public health outcomes, delegates at the 14th annual eyeforpharma conference in Barcelona have been told. Addressing over a thousand industry stakeholders at Barcelona’s Centre Convencions Internacional, senior…

R&D Almirall Portugal stopped all commercial activity in 2011 to focus only on the market access of new, innovative products being introduced through the organization’s active R&D pipeline. Country Manager Rui Santos explains this process and how he plans to tackle the tough Portuguese marketplace.   Almirall has been in Portugal…

Almirall Having only arrived on the market last year, the GM of Almirall in Canada explains the company’s regulatory struggles, the utilization of Almirall’s global R&D infrastructure in Canada as well as the company’s choice to enter the Canadian market and what products they are introducing into it.   You started…

Almirall Austria Almirall was opened through the acquisition of Hermal in 2007. What impact did that have on Almirall’s operations in central Europe, and where does Austria fit in Almirall’s picture today? Nowadays Almirall Austria plays a significant role amongst the Almirall-affiliates. The Austrian subsidiary has been meeting and exceeding the expectations…

Almirall Mexico Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process and the suppression of the manufacturing plant law have affected Almirall? At the moment, Almirall is present through affiliates in…

Almirall UK The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall was founded in 1943 in Barcelona (Spain) and in 1944 it started its industrial and commercial activity. In the 60s…